about
The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV AntibodiesPrevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE studyVirologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencingA Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep PyrosequencingHigh-resolution antibody dynamics of vaccine-induced immune responsesHuman responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangementsNext generation sequencing reveals the association of DRB3*02:02 with type 1 diabetes.Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencingMinority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.Convergent antibody signatures in human dengueHigh throughput HLA genotyping using 454 sequencing and the Fluidigm Access Array™ System for simplified amplicon library preparation.Characterization of Mauritian cynomolgus macaque major histocompatibility complex class I haplotypes by high-resolution pyrosequencing.Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory.Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedUltra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infectionAssuring the quality of next-generation sequencing in clinical laboratory practice.Low-frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in antiretroviral-naïve subjects.Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements.An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.Correction: The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies.Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.Therapy failure resulting from superinfection by a drug-resistant HIV variantRadicicol-sensitive peptide binding to the N-terminal portion of GRP94Designing and Implementing NGS Tests for Inherited Disorders: A Practical Framework with Step-by-Step Guidance for Clinical Laboratories
P50
Q27680688-625BF1FD-C845-479D-9745-BF0D557EE1B1Q28474221-5D355C7B-3273-4791-B879-2ED5DB8EB000Q28480762-C25F7DE3-CA00-470F-9EC1-72F08A5C9675Q28552356-731A3DCD-093B-4A4E-8F01-013E68BC57A2Q28660366-149E05D1-FF3A-4D7C-9979-E1E9060518BEQ30364187-B0D47305-F47F-4D56-BE98-1163A55FFD82Q30412114-B0015F54-7BB3-4AA4-8A1D-7EDCE5DD1EA3Q33531727-0BF0254D-3112-4451-89C5-E9F1B22BF2BAQ33601530-8440D649-5A0F-43CF-BF34-6AF8EB7F42B8Q34060276-D532FF7C-40B1-4CC3-869B-1E2729CDF074Q34582241-1B3DB132-8B72-426E-A326-DA52E21EA029Q34802023-CE2DDB34-48BB-4053-96B3-457B9C9FBAC0Q35377839-0B230944-A273-414C-A2AC-08AEE1AA3E1BQ35441583-B8C6D9A1-40D5-43A3-ABFD-E56BEB89E9D8Q35964704-0DDAA9D7-2245-4100-9F2D-096257F1C277Q36551179-930ED3FB-E6FE-4C70-A5F5-1729E29E1977Q37306277-DC92BADC-E732-4099-BF53-5DD6CE779A50Q41726095-6CA61F16-8364-4631-9A79-9287AF42FAC5Q41911217-3B61BA3D-3234-451D-8553-0620B7D6225AQ42219452-C2AE309B-6CF3-4AD7-904C-BF93764A14E2Q43889383-0125024B-66B0-46DA-A26F-9E7F420D5845Q46903330-E1CD7F09-18F4-4586-A700-E990F559AB05Q54562349-04F2B072-B739-4CF3-80C1-6F0B4289AA4DQ58422854-7639B8C5-A7FF-4D20-A7F5-7E38386B4E37Q74633065-844E836F-24F3-40D7-AA97-3E8E8FE410A1Q90865710-BB5460F7-B3F1-4E1E-9DAB-1AB88F53028E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Birgitte B Simen
@ast
Birgitte B Simen
@en
Birgitte B Simen
@es
Birgitte B Simen
@nl
type
label
Birgitte B Simen
@ast
Birgitte B Simen
@en
Birgitte B Simen
@es
Birgitte B Simen
@nl
prefLabel
Birgitte B Simen
@ast
Birgitte B Simen
@en
Birgitte B Simen
@es
Birgitte B Simen
@nl
P106
P108
P31
P496
0000-0003-0503-0973